4 stories mentioning VTRSUpdated 28d ago
Every FINWIRES story that references VTRS, newest first.
Viatris (VTRS) has an average rating of overweight and mean price target of $18.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $16.23, Change: $-0.04, Percent Change: -0.22%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to $18 from $17, 6.6x our 2027 EPS forecast, a discount to peers due to VTRS's slower growth prospects. We adjust our 2026 EPS estimate to $2.48 from $2.45 and maintain our 2027 EPS forecast at $2.72. Viatris reported a strong first quarter for 2026, with total revenues of $3.5B, up 4.7% Y/Y, above expectations, and adjusted EPS of $0.59. The Greater China segment was a standout performer, with revenue accelerating 18% Y/Y, significantly ahead of expectations. This was driven by favorable market fundamentals, strategic investments in selling and marketing, and a more than doubling of sales through e-commerce platforms. While the company raised its growth expectation for China for the full year from low-single digits to mid- to high-single digits, we think policy risks exist in a highly dynamic and unpredictable environment. Next, we see the upcoming U.S. launches of the weekly contraceptive patch XULANE LO and fast-acting meloxicam, to be a key focus to potentially accelerate growth.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Viatris delivered solid Q1 2026 results with revenues of $3.517B (+8% Y/Y), $150M above consensus, and adjusted EPS of $0.59 (+18% Y/Y), beating consensus by $0.09. Adjusted EBITDA grew 14% Y/Y to $1.049B, demonstrating meaningful operating leverage from the completed strategic review. The brands portfolio showed strong momentum with $2.3B in net sales (+10% Y/Y), driven by exceptional Greater China performance (+22% Y/Y) and continued Emerging Markets strength, while generics stabilized at $1.177B (+5% Y/Y). Management reaffirmed all 2026 guidance ranges, including total revenues of $14.45B-$14.95B and adjusted EPS of $2.33-$2.47, despite incorporating the February Nashik facility fire impact. New product development remained on track with $71M in Q1 revenues toward the $450M-$550M full-year target. In our view, the strategic review has been successful so far to drive operational improvements in Q1, while positioning Viatris for healthy growth.
Health care stocks were mixed premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) retreating by 0.1% and the iShares Biotechnology ETF (IBB) advancing 0.03%.Viatris (VTRS) shares rose more than 1% pre-bell after the company reported higher Q1 financial results and reaffirmed its 2026 guidance.
